Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

NCT02616640

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 102 Baltimore, Maryland, United States
  • Local Institution - 114 Boston, Massachusetts, United States
  • Local Institution - 108 Boston, Massachusetts, United States
  • Local Institution - 115 Boston, Massachusetts, United States
View all 22 locations
View Trial Details
Completed

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

NCT05199337

Conditions
AL Amyloidosis, Amyloidosis, Immune System Diseases, +10 more
Locations
  • University of Southern California Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Tulane University New Orleans, Louisiana, United States
  • Washington University St Louis, Missouri, United States
View all 21 locations
View Trial Details
Completed

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT02633059

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chromosome 17 deletion, +15 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

NCT04274738

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Mass General Hospital Cancer Center Boston, Massachusetts, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

NCT03110562

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Boca Raton Clinical Research (BRCR) Medical Center Plantation, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Kaiser Permanente Hawaii Honolulu, Hawaii, United States
  • McFarland Clinic Ames, Iowa, United States
View all 157 locations
View Trial Details

Related conditions